Trial Profile
A study evaluating treatment adherence in patients switching from deferasirox (DFX) dispersible tablet (DFX-DT) to film-coated tablet (DFX-FCT).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes; Sickle cell anaemia; Thalassaemia
- Focus Therapeutic Use
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 24 May 2017 Results (n=348) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 22 May 2017 New trial record